Friday, September 30, 2005

Diabetes - health


Pfizer Wins Panel Backing for First Inhaled Insulin (Update5)
Bloomberg.com - Sep 08 3:06 PM
Sept. 8 (Bloomberg) -- Pfizer Inc., the world's biggest drugmaker, won a U.S. committee's support for the first inhaled insulin as an alternative to needles for 4 million American diabetics.

Pfizer Wins Panel Backing for First Inhaled Insulin (Update4)
Bloomberg.com - Sep 08 2:26 PM
U.S. Sept. 8 (Bloomberg) -- Pfizer Inc., the world's biggest drugmaker, won a U.S. committee's support for the first inhaled insulin as an alternative to needles for 4 million American diabetics.

PROactive Study Shows Takeda's ACTOS(R) (pioglitazone HCl) Reduced Heart Attacks, Strokes and Deaths in Patients With
[Press Release] Market Wire via Yahoo! Finance - Sep 12 8:08 AM
Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes demonstrated that ACTOS significantly reduced the combined risk of heart attacks, strokes and death by 16% in high-risk patients with type 2 diabetes.

Pfizer Wins Panel Backing for First Inhaled Insulin (Update5)
Bloomberg.com - Sep 08 3:13 PM
Sept. 8 (Bloomberg) -- Pfizer Inc., the world's biggest drugmaker, won a U.S. committee's support for the first inhaled insulin as an alternative to needles for 4 million American diabetics.

Lilly's Withdrawal of Human Insulin Has Veterinary Ramifications
[Press Release] Business Wire via Yahoo! Finance - Sep 08 12:55 PM
Eli Lilly and Company's forthcoming discontinuation of four human insulin products has surprised an unlikely group of doctors -- veterinarians -- as they scramble to plan for treatment of dogs with diabetes.

PRESERVE- 2-year study of initial combo therapy with nateglinide or glyburide + metformin
EurekAlert! - Sep 28 1:51 PM
East Hanover, June 13, 2005 Researchers reported yesterday that in a two-year, controlled study people with type 2 diabetes receiving Starlix (nateglinide) in combination with metformin experienced equivalent levels of overall blood glucose control and a lower incidence and severity of hypoglycemia compared to the those taking the commonly used sulfonylurea agent, glyburide, in combination

Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency
[Press Release] Business Wire via Yahoo! Finance - Sep 29 1:05 PM
Insmed Incorporated provided an update on its ongoing pivotal clinical trial of iPlex for the treatment of children with growth failure who suffer from Severe Primary IGF-1 deficiency .

Study shows ACTOS reduced heart attacks, strokes and deaths in patients with type 2 diabetes
EurekAlert! - Sep 12 10:22 AM
Lincolnshire, Ill., September 12, 2005 Landmark data from the PROactive Study, presented today at the 41st meeting of the European Association for the Study of Diabetes (EASD) demonstrated that ACTOS (pioglitazone HCl) significantly reduced the combined risk of heart attacks, strokes and death by 16% in high-risk patients with type 2 diabetes.

Pfizer Wins Panel Backing for First Inhaled Insulin (Update5)
Bloomberg.com - Sep 08 3:11 PM
U.S. Sept. 8 (Bloomberg) -- Pfizer Inc., the world's biggest drugmaker, won a U.S. committee's support for the first inhaled insulin as an alternative to needles for 4 million American diabetics.
http://diabetes-hypoglycemiasite.com/health/index.html

0 Comments:

Post a Comment

<< Home